Jefferies Financial Group Inc. significantly reduced its stake in The Travelers Companies, Inc. by 96.7% in the fourth quarter, selling 23,203 shares and retaining only 796 shares. Despite this large sale by Jefferies, Travelers Companies reported strong financial results, including beating EPS estimates, higher revenue, and an increased quarterly dividend. The company also maintains a "Hold" consensus rating from Wall Street analysts with an average price target of $311.47, though some insider selling has also occurred.

Jefferies Financial Group Inc. significantly reduced its stake in Targa Resources, Inc. by selling 9,263 shares, cutting its holdings by 84% to 1,763 shares valued at approximately $325,000. This institutional selling was accompanied by insider sales from Targa Resources executives. Despite the sales and a recent earnings miss, analysts maintain a "Moderate Buy" rating for Targa Resources with an average price target of $269.21.

Jefferies Financial Group Inc. significantly reduced its stake in Johnson Controls International plc by selling 34,020 shares, lowering its position by 93.5%. This transaction leaves Jefferies with 2,380 shares valued at approximately $285,000. Concurrently, a corporate insider, VP Lei Zhang Schlitz, also sold 88,809 shares for roughly $12.5 million, cutting their ownership by over 60%.

Karras Company Inc. recently acquired 7,391 shares of JPMorgan Chase & Co. for approximately $2.38 million in the fourth quarter, making it their 14th largest holding. Institutional interest in JPM remains strong, with 71.55% of the stock owned by such investors, despite some insider selling. JPMorgan also announced a $1.50 quarterly dividend and recent earnings beat expectations, though CEO Jamie Dimon has expressed caution regarding market exuberance.

Moderna and CEPI have expanded their collaboration to advance a potential vaccine against the Bundibugyo ebolavirus (BDBV), with CEPI committing up to $50 million. This funding will support preclinical work, Phase 1 clinical testing, and parallel manufacturing using Moderna's mRNA platform. The aim is to accelerate readiness for rapid progression to Phase 2/3 trials, addressing a current outbreak that has caused over 900 suspected cases and 220 suspected deaths.

Just three weeks into his new role as CEO of NRG Energy, Rob Gaudette is already outlining his leadership vision. He shared his plans with the Houston Business Journal while volunteering at Habitat for Humanity during NRG Impact Week. Gaudette emphasized that he views the job as a responsibility much larger than himself.

Even with a forecast of a "below normal" hurricane season, Florida's largest electric utilities, Florida Power & Light (FPL) and Duke Energy, work year-round to prepare for potential storms. Both companies conduct annual simulated hurricane drills and have invested heavily in infrastructure improvements to minimize power outages and speed up restoration times. They also provide comprehensive advice for Floridians on how to prepare for hurricane season.

Legal & General Group Plc reduced its stake in Huntington Ingalls Industries (HII) by 17.7% in Q4, selling 13,865 shares but still holding 64,264 shares valued at $21.9 million. This occurred as other institutional investors made various moves, maintaining high institutional ownership at 90.46%, while insiders sold 9,600 shares. The company recently reported strong quarterly results, with EPS topping estimates and revenue up 13.4%, and also declared a quarterly dividend of $1.38 per share.

Legal & General Group Plc has reduced its stake in Skyworks Solutions, Inc. by 15.9% in the fourth quarter, selling 77,460 shares, now holding 409,744 shares valued at approximately $26 million. Despite cautious analyst sentiment with a "Hold" rating, Skyworks reported stronger-than-expected fiscal Q2 earnings of $1.15 per share on revenues of $943.7 million and declared a quarterly dividend of $0.71 per share. The company's stock has a market cap of $11.71 billion and a PE ratio of 32.30.

Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI) have expanded their collaboration to develop a potential vaccine against Bundibugyo ebolavirus (BDBV). CEPI is committing up to $50 million to support preclinical development and Phase 1 clinical testing of Moderna's mRNA-based vaccine candidate, including parallel manufacturing activities. This initiative leverages Moderna's rapid development and scalability capabilities, aiming to accelerate the availability of a vaccine for a disease with no currently licensed prevention.